Why Target Aging?
Over the past two centuries, life expectancy in Western countries has drastically increased, with projections indicating that more than one-fifth of the global population will be older than 60 years by the year 2050. Accordingly, aging is the primary risk factor for most chronic diseases in humans, from cancer to Alzheimer’s.
As aging and age-associated diseases become an increasingly significant societal burden, there is an urgent need to develop effective strategies to mitigate their impact. The rising prevalence of chronic conditions that are predominantly caused by aging poses challenges not only to healthcare systems but also to the quality of life of the aging population.
Without addressing the root cause, biological aging, treating one disease only delays the onset of another. By extending healthspan, we can reduce disease burden, improve quality of life, and boost economic value across society.
Our Approach
Biological aging drives the decline of cellular function, leading to disease. Targeting its root mechanisms opens new doors for longevity. Our technology resets cellular aging markers, enabling safe, scalable and cost-effective rejuvenation. We develop the first chemical reprogramming platform to reverse aging, not just delay it, and go beyond traditional drug development by addressing all aging pathways at once. With a strong scientific foundation, biotech business expertise, and a clear roadmap, we are pioneering a new class of reprogramming therapeutics to target aging at its root.
Our Expertise in Reprogramming
Schoenfeldt et al.
EMBO Molecular Medicine
Parras et al.
Nature Aging
Phelps et al.
Aging Cell
Pico et al.
Cell ReportsThe Team
Lucas Schoenfeldt, Ph.D
CEO, Co-founder
Lucas holds a PhD in aging and reprogramming. He is an expert in reprogramming, C. elegans, killifish, and mouse experimentation. He has published high-impact work on chemical reprogramming and longevity, and has experience in biotech, drug discovery, and translational research.
Théo Aspert, Ph.D
CSO, Co-founder
Théo holds a PhD in aging and is a researcher at EPFL. He is an expert in human cell biology, bioengineering, and automation. He has 9 years of research experience and 2 years in biotech and aging startups, and is an award-winning scientist with multiple high-impact publications.
Alberto Parras, Ph.D
Strategic partner, Co-founder
Alberto is the Founder & CEO of VivoArchitect, an aging preclinical CRO. He is a serial entrepreneur with businesses across Europe, possesses extensive experience in in vivo reprogramming and drug discovery in AADs, and is a recipient of numerous awards, reports, and patents.
Advisory board
Michael Snyder, PhD
Stanford University
Michael is the Chair of Genetics & Director of Personalized Medicine. He is a leader in aging biomarkers, multi-omics, and personalized health. He is a major participant of the ENCODE project, has over 800 publications, and is a co-founder of 18 companies.
Adam Antebi, PhD
Max Planck Institute
Adam is the Director of the Max Planck Institute for Biology of Ageing. He is a pioneer in the molecular genetics of aging and longevity across species, and a keynote speaker and advisor to global science initiatives.
David Vilchez, PhD
University of Cologne
David is a Professor at CECAD & Institute for Genetics. He is a leader in aging and proteostasis research, an ERC & Marie Curie grantee, and a high-impact researcher on aging and neurodegeneration.
Soumya Banerjee, PhD
Strategic Partner, CEO & Co-founder of Juvion Health Science
Soumya holds a PhD in aging and neurodegeneration. Juvion Health Science advances next-generation therapeutics to prevent age-related neuromuscular diseases.
Our Presence
- Swiss Biotech Day (Basel, April 2024)
- BSNL BioScience Network (Lausanne, April 2024, pitching)
- Digital Vivarium Forum (Buguggiate April 2024)
- Life Science Career Day (Lausanne, May 2024, booth sponsorship)
- Startup Day Switzerland (Bern, May 2024)
- Aging Research and Drug Discovery Meeting (Copenhagen, August 2024)
- Open Innovation in Life Sciences (Zurich, October 2024)
- Future Health Lausanne (Lausanne, October 2024)
- SGV Meeting 2024 (Lausanne, November 2024)
- Biopole Discovery Day (Epalinges, March 2025)
- Transfer Meeting (Sevilla, June 2025)
- Biotech Annual Congress (Malaga, July 2025)
Location
Rever is proudly based in Lausanne, Switzerland, a vibrant hub for innovation and biotechnology.
